Fluorouracil (5-fluorouracil/5-FU) 250mg
Product Overview
| Generic Name | Fluorouracil (5-fluorouracil/5-FU) 250mg |
| Brand Name(s) | Adrucil |
| Category | Antineoplastic / Cancer |
| Form | Vial, Sterile solution for injection / IV infusion |
| Strength | 250 mg / 5 mL, equivalent to 50 mg/mL |
| Therapeutic Class | Antineoplastic antimetabolite; fluorinated pyrimidine / pyrimidine analogue; nucleoside metabolic inhibitor |
| ATC Code | L01BC02 |
Manufacturing & Regulatory
| Manufacturer | Celon, Accord |
| GMP Compliance | WHO-GMP |
| COFEPRIS | 010.000.3012.00 |
| Free Sale Certificate | Yes, available as COPP/CPP |
Logistics & Export
| MOQ | 10 Units |
| Shelf Life | 24 Months |
| Storage | Store at 20–25 °C |
| Incoterms | ExW, 30049042 |
| Lead Time | 7 - 10 Business Days |
Documentation Available Upon Request
| Certificate of Analysis (PDF) | Supplied per batch upon request |
| SDS-Safety Data Sheet (PDF) | Upon Request, not publicly posted |
| CTD Summary (PDF) | CTD proprietary; available under commercial agreement/license |
Special Notes
Each box contains 10 vials
Fluorouracil Injection is a cytotoxic antimetabolite chemotherapy agent used in oncology, commonly as part of combination regimens for colorectal, breast, gastric/stomach, pancreatic, and other solid tumours, depending on the approved local label and treatment protocol. It inhibits DNA synthesis through thymidylate synthase inhibition and may also interfere with RNA function.